A CR-UK phase I dose escalation study of BKM120 in patients with non-small cell lung cancer (NSCLC) receiving thoracic radiotherapy
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2018
At a glance
- Drugs Buparlisib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 21 Nov 2017 Status changed from active, no longer recruiting to completed.
- 29 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated